Hedwig Blommestein

Hedwig Blommestein is an Associate Professor at the Erasmus School of Health Policy & Management, specializing in Health Technology Assessment (HTA). Her research focuses on cost-effectiveness analysis in oncology, particularly for Melanoma, Breast Cancer, and Multiple Myeloma therapies.

• Erasmus University Rotterdam
• Health Technology Assessment (HTA) department

Research interests include:

• Health economics of novel cancer treatments
• Proton therapy outcomes
• Quality of life assessments
• Treatment sequencing models

Recent work spans 55 publications (2025–2015) in journals like Nature, Medical Decision Making, and European Journal of Cancer, covering topics from BRAF-mutant melanoma modeling to societal impacts of CDK4/6 inhibitors.

She contributes to datasets on survival extrapolation (2023) and surrogate endpoints (2021) via platforms like Figshare. Key collaborations include the SONIA Study Consortium and Dutch hematological registries.